Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902472 · ClinicalTrials.gov registry record
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
A clinical trial, sponsored by Gilead Sciences.
- Completed
- Registry status
- 172
- Enrollment target
NCT01902472 is a clinical trial that has completed, run by Gilead Sciences. The registered enrollment target is 172 participants.
The verdict
NCT01902472 has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 172 participants
- Enrollment target
Study Summary
This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2013-09-02 |
| Est. Completion | 2017-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902472
The ClinicalTrials.gov registry entry for NCT01902472 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01902472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01902472 about?
NCT01902472 is a clinical study titled "A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)". This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs ...
What is the current status of trial NCT01902472?
This trial is currently completed. The enrollment target is 172 participants. The study started on 2013-09-02. Estimated completion is 2017-10-30.
Who is sponsoring clinical trial NCT01902472?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.